PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medicine, University of Alabama at Birmingham, AL, USA.\', \'Sanofi Pasteur, Swiftwater, PA, USA.\', \'Sanofi Pasteur, Lyon, France.\', \'Rochester Clinical Research, Rochester, NY, USA.\', \'Meridian Clinical Research, Omaha, NE, USA.\', \'Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.\', \'University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.\', \'GlaxoSmithKline Vaccines, Wavre, Belgium.\', \'Optimal Research, Melbourne, FL, USA.\', \'Research Centers of America, Hollywood, FL, USA.\', \'Peninsula Research Associates, Rolling Hills Estates, CA, USA.\', \'Sanofi Pasteur, Swiftwater, PA, USA. Electronic address: guy.debruyn@sanofi.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1473-3099(21)00147-X10.1016/S1473-3099(21)00147-X
?:hasPublicationType
?:journal
  • The Lancet. Infectious diseases
is ?:pmid of
?:pmid
?:pmid
  • 33887209
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33887209>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33887209>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all